A new explainer compares male testosterone decline with menopause. EAU guidance adds context on total testosterone, free testosterone and SHBG.
On October 14, 2026, HB Mag published “What Is Menopause For Men? What It Really Means” under the byline HB Mag Health Research Team. The explainer described male testosterone decline as gradual and variable rather than an abrupt menopause-like shutdown.
This article is for informational purposes only and is not medical advice. Personal questions about symptoms or hormone treatment belong with a qualified clinician.
The phrase suggests a shared biological turning point. HB Mag’s central distinction is that male testosterone production does not abruptly stop in the way the menopause comparison implies. Its account describes changes over decades, with considerable differences between men.
The explainer says some older men retain testosterone levels within the range considered normal for younger men. Others experience declines earlier. That variation matters because a broad description of aging does not describe every man’s hormone status.
HB Mag outlines a feedback system involving the hypothalamus, pituitary gland and testes. This system regulates testosterone production. Most testosterone comes from the testes, with a smaller amount coming from the adrenal glands.
For readers seeking the wider biological context, Testostra’s guide to how testosterone production connects with tissue effects provides a broader framework. Here, the important distinction is between a regulated system that continues producing testosterone and the idea of an age-related switch being turned off.
The European Association of Urology (EAU) guideline gives the comparison a more precise clinical frame. It describes age-related testosterone decline in healthy men as small and gradual. That is a different claim from saying that aging itself creates a hormone deficiency requiring treatment.
A discussion of “testosterone levels” needs to identify which measurement it means. Total testosterone measures the overall amount in blood. Free testosterone is the unbound fraction.
The EAU guideline reports European Male Ageing Study estimates of a 0.4% annual decrease in total testosterone and a 1.3% annual decrease in free testosterone. These are distinct estimates for distinct measurements. Treating them as interchangeable would erase a clinically relevant difference.
Sex hormone-binding globulin, usually shortened to SHBG, helps explain why interpretation becomes more complicated. The EAU notes that aging is associated with increased SHBG and that total testosterone varies with circulating SHBG. A total testosterone value therefore needs to be considered alongside factors that affect this binding protein.
The practical distinction is straightforward:
According to the EAU guideline, free testosterone assessment can help when SHBG is altered. The guideline identifies age, obesity and insulin resistance among the factors that can affect SHBG. It particularly notes the potential value of free testosterone assessment in older men with obesity.
The guideline identifies equilibrium dialysis as the most accurate method for measuring free testosterone. It also describes calculated free testosterone using SHBG and albumin as an alternative. These are approaches to clinical interpretation, not interchangeable labels that can be added to any laboratory result without considering the method used.
The useful question is therefore not simply whether testosterone has fallen. It is which measurement has changed and whether binding-related factors affect its meaning. That distinction is more informative than a single headline rate of decline.
The EAU guideline places considerable emphasis on health context. It states that obesity and comorbidities account for many cases of functional hypogonadism. This prevents an age-only explanation from taking over the discussion.
That framing separates two questions: what happens to testosterone across aging populations, and what may be contributing to a particular man’s low result. The first concerns a general trend. The second requires a clinical assessment that considers symptoms and biochemical findings.
For someone researching midlife changes, this distinction shifts attention away from finding a label that seems to fit. It directs attention toward the evidence a clinician would need to explain the concern. In the EAU framework, age sits alongside other health factors rather than replacing them.
HB Mag’s article is an accessible explanation rather than a new clinical study or guideline. Its central menopause comparison is useful, but several details need a more careful reading.
The explainer says testosterone falls by roughly 1% per year after about age 30 in many men. It does not identify the underlying studies or provide their methods, populations or estimates of uncertainty. That makes the figure less informative than a study-specific estimate tied to a clearly identified measurement.
The EAU’s separate estimates for total and free testosterone show why a single shorthand rate leaves important information out. Population estimates also should not be used as a personal forecast. They do not establish how quickly an individual man’s testosterone will change.
HB Mag contradicts itself about SHBG: one passage says it falls with age, while another says it rises. The EAU guideline supports increased SHBG as an age-associated factor. The explainer’s statement that SHBG falls should therefore not be carried forward as an established explanation of aging.
This is a consequential distinction rather than a minor wording issue. SHBG is part of the explanation for why total and free testosterone may tell different stories. An inconsistent account of its direction makes that explanation harder to follow.
The explainer notes that symptoms attributed to low testosterone can overlap with poor sleep, depression and thyroid problems. It also identifies medication effects and other health conditions as possible explanations. A symptom list does not distinguish among those causes.
The EAU addresses this uncertainty by requiring compatible signs and symptoms together with biochemical evidence. For readers, the practical implication is to treat symptoms as a subject for evaluation rather than as confirmation of a hormone diagnosis. Testostra’s discussion of how symptoms and hormone results are considered together offers related context.
No immediate change in medical practice follows from this explainer. It introduces neither new treatment evidence nor a new diagnostic recommendation. Its value is in prompting a clearer explanation of male hormonal aging.
The EAU guideline remains the relevant clinical reference in this comparison. It recommends assessing late-onset hypogonadism through compatible signs and symptoms plus low morning total testosterone confirmed on at least two occasions. A diagnosis is not established by one low result.
The guideline recommends fasting total testosterone measurement between 07:00 and 10:00. It also recommends repeat measurements on separate occasions when levels are below its stated threshold before testosterone therapy begins. These are guideline standards for clinician-led assessment, not a self-diagnosis protocol.
Collection circumstances matter within that assessment. The EAU advises against testosterone measurement during acute disease because acute illness can cause functional hypogonadism. It also notes that non-fasting testing can underestimate total testosterone and that sampling schedules may need to account for night-shift work.
Those details explain why comparing laboratory numbers without their collection context can be misleading. Testostra’s overview of the process from an initial result to confirmation addresses that part of the evaluation.
A clinical discussion can focus on a few evidence-based questions:
These questions follow the EAU’s emphasis on symptoms, repeat measurements and appropriate interpretation of related biomarkers. They keep the discussion focused on evidence rather than on whether the phrase “male menopause” feels familiar.
The bottom line is that the explainer supports clearer language, not a new reason to start testosterone replacement therapy. Decisions about testing and treatment remain matters for qualified care using the person’s symptoms, confirmed results and clinical context.
Choosing whether age-related symptoms need clinical assessment goes beyond the phrase “male menopause”; Testostra supports understanding of the evidence behind that decision. Its writing on low testosterone and emerging research addresses uncertainty about symptoms and possible causes, with clear separation between general education and personal medical advice.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra